# US 2025/0367270 A1 · Symmetry based viral antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367270 A1
- Document ID: US20250367270A1
- Status: Published application
- Kind: A1
- Application number: 18/873,295
- Filed: 2023-06-09
- Published: 2025-12-04
- Earliest claimed: 2022-06-10
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: John C. WILLIAMS; Miso PARK; Juliet GONZALES
- Web page: https://patentgrep.com/patent/US20250367270A1

## CPC

- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- C12Y 304/17023: Angiotensin-converting enzyme 2 (3.4.17.23)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/70: containing domain for protein-protein interaction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.

## Claims

### Claim 1

A peptide comprising a collagen trimerizing domain bound to a viral protein binding domain through a chemical linker.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is bound to the C-terminus of said collagen trimerizing domain.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is a Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV) protein binding domain.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is a viral envelope protein binding domain.

### Claim 5 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is a spike protein binding domain.

### Claim 6 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is a SARS CoV-2 protein binding domain.

### Claim 7 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is a SARS CoV-2 RBD binding domain.

### Claim 8 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain is an angiotensin converting enzyme 2 (ACE2) domain.

### Claim 9 (depends on 1)

The peptide of claim 1, wherein said viral protein binding domain comprises the sequence of SEQ ID NO: 1.

### Claim 10 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain is a collagen 18 trimerizing domain, a collagen 1 trimerizing domain or a collagen 2 trimerizing domain.

### Claim 11 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain is a collagen 18 trimerizing domain.

### Claim 12 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain comprises the sequence of SEQ ID NO:2 or SEQ ID NO:3.

### Claim 13 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain comprises the sequence of SEQ ID NO:2.

### Claim 14 (depends on 1)

The peptide of claim 1, wherein said chemical linker is a covalent linker.

### Claim 15 (depends on 1)

The peptide of claim 1, wherein said chemical linker is a peptide linker.

### Claim 16 (depends on 15)

The peptide of claim 15, wherein said peptide linker comprises one or more glycine amino acid residues.

### Claim 17 (depends on 15)

The peptide of claim 15, wherein said peptide linker has a length of less than 20 amino acid residues.

### Claim 18 (depends on 15)

The peptide of claim 15, wherein said peptide linker has a length from about 1 to about 15 amino acid residues.

### Claim 19 (depends on 15)

The peptide of claim 15, wherein said peptide linker has a length of 3, 5, 7, 9, or 18 amino acid residues.

### Claim 20 (depends on 15)

The peptide of claim 15, wherein said peptide linker has a length of about 3 amino acid residues.

### Claim 21 (depends on 15)

The peptide of claim 15, wherein said peptide linker comprises the sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:24.

### Claim 22 (depends on 15)

The peptide of claim 15, wherein said peptide linker comprises the sequence of SEQ ID NO:4 or SEQ ID NO:24.

### Claim 23 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain is a human collagen trimerizing domain.

### Claim 24 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain is non-immunogenic.

### Claim 25 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain does not include amino acid substitutions or amino acid variants.

### Claim 26 (depends on 1)

The peptide of claim 1, wherein said collagen trimerizing domain does not include a foldon domain or portion thereof.

### Claim 27 (depends on 1)

The peptide of claim 1, wherein the N-terminus of said viral protein binding domain is bound to a viral protein.

### Claim 28 (depends on 27)

The peptide of claim 27, wherein said viral protein is a Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV) protein.

### Claim 29 (depends on 27)

The peptide of claim 27, wherein said viral protein is a viral envelope protein.

### Claim 30 (depends on 27)

The peptide of claim 27, wherein said viral protein is a spike protein.

### Claim 31 (depends on 27)

The peptide of claim 27, wherein said viral protein is a SARS CoV-2 protein.

### Claim 32 (depends on 27)

The peptide of claim 27, wherein said viral protein is a SARS CoV-2 RBD.

### Claim 33 (depends on 1)

The peptide of claim 1, wherein said peptide comprises the sequence of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:25.

### Claim 34 (depends on 1)

The peptide of claim 1, wherein said peptide comprises the sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO: 18, SEQ ID NO:19 or SEQ ID NO:25.

### Claim 35 (depends on 1)

The peptide of claim 1, wherein said peptide is a first peptide and said collagen trimerizing domain is a first trimerizing collagen domain.

### Claim 36 (depends on 35)

The peptide of claim 35, wherein said first collagen trimerizing domain is bound to:
(i) a second peptide comprising a second collagen trimerizing domain bound to a second viral protein binding domain through a second chemical linker; and
(ii) a third peptide comprising a third collagen trimerizing domain bound to a third viral protein binding domain through a third chemical linker;
wherein said first collagen trimerizing domain, said second collagen trimerizing domain and said third collagen trimerizing domain are covalently bound together thereby binding said first peptide, said second peptide and said third peptide together.

### Claim 37 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain is bound to the C-terminus of said first collagen trimerizing domain.

### Claim 38 (depends on 36)

The peptide of claim 36, wherein said second viral protein binding domain is bound to the C-terminus of said second collagen trimerizing domain.

### Claim 39 (depends on 36)

The peptide of claim 36, wherein said third viral protein binding domain is bound to the C-terminus of said third collagen trimerizing domain.

### Claim 40 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain are independently a Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV) protein binding domain.

### Claim 41 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain are independently a viral envelope protein binding domain.

### Claim 42 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain are independently a spike protein binding domain.

### Claim 43 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain are independently a SARS CoV-2 protein binding domain.

### Claim 44 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain are independently a SARS CoV-2 RBD binding domain.

### Claim 45 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain are independently an angiotensin converting enzyme 2 (ACE2) domain.

### Claim 46 (depends on 36)

The peptide of claim 36, wherein said first viral protein binding domain, said second viral protein binding domain and said third viral protein binding domain independently comprise the sequence of SEQ ID NO: 1.

### Claim 47 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said second collagen trimerizing domain and said third collagen trimerizing domain are independently a collagen 18 trimerizing domain, a collagen 1 trimerizing domain or a collagen 2 trimerizing domain.

### Claim 48 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said second collagen trimerizing domain and said third collagen trimerizing domain are independently a collagen 18 trimerizing domain.

### Claim 49 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said second collagen trimerizing domain and said third collagen trimerizing domain independently comprise the sequence of SEQ ID NO:2 or SEQ ID NO: 3.

### Claim 50 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said second collagen trimerizing domain and said third collagen trimerizing domain independently comprise the sequence of SEQ ID NO: 2.

### Claim 51 (depends on 36)

The peptide of claim 36, wherein said first chemical linker, said second chemical linker and said third chemical linker are independently a covalent linker.

### Claim 52 (depends on 36)

The peptide of claim 36, wherein said first chemical linker, said second chemical linker and said third chemical linker are independently a peptide linker.

### Claim 53 (depends on 52)

The peptide of claim 52, wherein said peptide linker comprises one or more glycine amino acid residues.

### Claim 54 (depends on 52)

The peptide of claim 52, wherein said peptide linker has a length of less than 20 amino acid residues.

### Claim 55 (depends on 52)

The peptide of claim 52, wherein said peptide linker has a length from about 1 to about 15 amino acid residues.

### Claim 56 (depends on 52)

The peptide of claim 52, wherein said peptide linker has a length of 3, 5, 7, 9, or 18 amino acid residues.

### Claim 57 (depends on 52)

The peptide of claim 52, wherein said peptide linker has a length of about 3 amino acid residues.

### Claim 58 (depends on 52)

The peptide of claim 52, wherein said peptide linker comprises the sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:24.

### Claim 59 (depends on 52)

The peptide of claim 52, wherein said first chemical linker is a first peptide linker, said second chemical linker is a second peptide linker and said third chemical linker is a third peptide linker.

### Claim 60 (depends on 59)

The peptide of claim 59, wherein said first peptide linker comprises the sequence of SEQ ID NO:4 or SEQ ID NO:24, said second peptide linker comprises the sequence of SEQ ID NO:4 or SEQ ID NO:24, and said third peptide linker comprises the sequence of SEQ ID NO:4 or SEQ ID NO:24.

### Claim 61 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said collagen trimerizing domain and said third collagen trimerizing domain are independently a human collagen trimerizing domain.

### Claim 62 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said collagen trimerizing domain and said third collagen trimerizing domain are independently non-immunogenic.

### Claim 63 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said collagen trimerizing domain and said third collagen trimerizing domain independently do not include amino acid substitutions or amino acid variants.

### Claim 64 (depends on 36)

The peptide of claim 36, wherein said first collagen trimerizing domain, said collagen trimerizing domain and said third collagen trimerizing domain independently do not include a foldon domain or portion thereof.

### Claim 65 (depends on 36)

The peptide of claim 36, wherein the N-terminus of said first viral protein binding domain is bound to a first viral protein, the N-terminus of said second viral protein binding domain is bound to a second viral protein and the N-terminus of said third viral protein binding domain is bound to a third viral protein.

### Claim 66 (depends on 65)

The peptide of claim 65, wherein said first viral protein, said second viral protein and said third viral protein form part of trimeric viral protein.

### Claim 67 (depends on 66)

The peptide of claim 66, wherein said trimeric viral protein is a Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV) protein.

### Claim 68 (depends on 66)

The peptide of claim 66, wherein said trimeric viral protein is a viral envelope protein.

### Claim 69 (depends on 66)

The peptide of claim 66, wherein said trimeric viral protein is a spike protein.

### Claim 70 (depends on 66)

The peptide of claim 66, wherein said trimeric viral protein is a SARS CoV-2 protein.

### Claim 71 (depends on 66)

The peptide of claim 66, wherein said trimeric viral protein is a SARS CoV-2 RBD.

### Claim 72 (depends on 36)

The peptide of claim 36, wherein said first peptide, said second peptide and said third peptide are chemically different or the same.

### Claim 73 (depends on 36)

The peptide of claim 36, wherein said first peptide, said second peptide and said third peptide independently comprise the sequence of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:25.

### Claim 74 (depends on 36)

The peptide of claim 36, wherein said first peptide, said second peptide and said third peptide independently comprise the sequence of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:25.

### Claim 75

A peptide complex comprising:
(i) a first peptide comprising a first collagen trimerizing domain bound to a first viral protein binding domain through a first chemical linker;
(ii) a second peptide comprising a second collagen trimerizing domain bound to a second viral protein binding domain through a second chemical linker; and
(ii) a third peptide comprising a third collagen trimerizing domain bound to a third viral protein binding domain through a third chemical linker;
wherein said first collagen trimerizing domain, said second collagen trimerizing domain and said third collagen trimerizing domain are covalently bound together thereby binding said first peptide, said second peptide and said third peptide together.

### Claim 76 (depends on 75)

The peptide complex of claim 75, wherein said first viral protein binding domain is bound to the C-terminus of said first collagen trimerizing domain.

### Claim 77 (depends on 76)

The peptide complex of claim 76, wherein said second viral protein binding domain is bound to the C-terminus of said second collagen trimerizing domain.

### Claim 78 (depends on 75)

The peptide complex of claim 75, wherein said third viral protein binding domain is bound to the C-terminus of said third collagen trimerizing domain.

### Claim 79 (depends on 1)

An isolated nucleic acid encoding a peptide of claim 1.

### Claim 80 (depends on 79)

An expression vector comprising the nucleic acid of claim 79.

### Claim 81 (depends on 80)

The expression vector of claim 80, wherein said expression vector is a viral vector.

### Claim 82 (depends on 1)

A method of treating a viral disease in a subject in need thereof, said method comprising administering to a subject a therapeutically effective amount of the peptide of claim 1, thereby treating an infectious disease in said subject.

### Claim 83 (depends on 82)

The method of claim 82, wherein said viral disease is SARS.

### Claim 84 (depends on 82)

The method of claim 82, wherein said viral disease is COVID-19.

### Claim 85 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the peptide of claim 1 and a pharmaceutically acceptable excipient.
